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Undertreatment of Women With Locoregionally Advanced  
Head and Neck Cancer
Annie Park, MD 1; Amy Alabaster, MS2; Hanjie Shen, MS3; Loren K. Mell, MD3,4; and Jed A. Katzel, MD5
BACKGROUND: It is difficult to predict whether a patient with head and neck cancer (HNC) is more likely to die of the cancer or 
 another comorbidity. Competing event models can help to identify individual patients or groups of patients who may be under-
treated or overtreated in clinical practice. METHODS: Patients with HNC (n = 884), aged 18 to 85 years and diagnosed from 2000 to 
2015 with stage II to IVB disease according to the seventh edition of the American Joint Committee on Cancer system, were identi-
fied. With a generalized competing event (GCE) model that controlled for age, sex, tumor site, surgical treatment, and Charlson 
Comorbidity Index (CCI), the association between these factors and the relative hazard for cancer mortality was determined. Logistic 
regression models were used to estimate the odds of receiving platinum-based chemoradiotherapy or a less intensive therapy, with 
adjustments made for age, sex, tumor site, CCI, stage, smoking, and alcohol abuse history. RESULTS: Compared with men, women 
had an increased relative hazard ratio for death from HNC versus other causes, which was reported as an adjusted ω+ ratio compar-
ing women with men (ω+ ratio, 1.95; 95% CI, 1.09-3.49), even though they were less likely to receive intensive chemoradiotherapy 
than men (adjusted odds ratio, 0.69; 95% CI, 0.48-0.99). CONCLUSIONS: These findings indicate that women in this cohort may be 
undertreated in clinical practice and potentially miss the opportunity for their HNC to be aggressively treated. This study supports 
the use of GCE models to identify patients who are potentially undertreated and may also help to guide future research in health 
disparities. Cancer 2019;0:1-7. © 2019 American Cancer Society. 
KEYWORDS: chemotherapy, head and neck cancer, health care disparities, morbidity.
INTRODUCTION
Head and neck cancer (HNC) accounts for approximately 4% of all cancers diagnosed in the United States.1 The inci-
dence rates for cancers of the oral cavity and pharynx, as reported by the American Cancer Society in 2017, were more 
than twice as high in men as in women.2 The treatment for patients with HNC varies by the primary site and by the 
stage of the disease. Curative treatment for locally advanced HNC often involves a combination of modalities, including 
surgery, radiation, and/or chemotherapy. Organ-sparing approaches for locally advanced, nonmetastatic HNC have 
shown that patients benefit from the addition of chemotherapy to radiation,3-6 although the addition of concurrent 
chemoradiotherapy is not clearly associated with an incremental advantage in older patients.7,8 Indeed, in clinical prac-
tice, many patients, especially older patients and those with significant comorbidities, may be treated with less intensive 
treatments such as cetuximab with radiation9 and radiation therapy alone or even no treatment.10 The optimal selection 
of patients for intensive treatment is not standardized and remains controversial.
Several health disparities in patients with HNC have been identified previously. Higher socioeconomic status and 
health insurance status have been associated with improved survival.11,12 Racial disparities have also been described in 
patients with HNC.11,13-18 However, sex disparities and patient outcomes remain less clearly delineated. Some studies 
have demonstrated no difference in survival between women and men,11,19-21 whereas other studies have found differ-
ences in survival. For example, Choi et al11 reported that women had better survival, whereas others found that outcomes 
for men improved over time.22,23
Generalized competing event (GCE) modeling is a useful and relatively novel method for analyzing effects of 
treatment and risk factors on outcomes.21,24,25 This approach has been validated for several cancers, including head and 
neck, endometrial, prostate, and breast cancer.24,26 The GCE model differentiates patients according to their hazard 
for an event of interest, such as cancer recurrence or mortality, with respect to competing events, such as death from 
noncancer causes, and this makes it useful for identifying individual patients who may benefit from intensive treatment 
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and groups of patients who may be undertreated.24 The 
advantage of GCE models over standard prognos-
tic models lies in assessing the extent to which a factor 
affects the ratio of a primary event to a competing event 
(ie, ω+) or the proportion of an overall event hazard attrib-
utable to a primary event (ie, ω). A recent publication has 
also found that the GCE model can reduce the cost and 
duration of cancer clinical trials through better risk strat-
ification.27 In this study, we applied the GCE model to 
evaluate a large cohort of patients in Northern California 
with HNC with the goal of comparing cause-specific 
survival between women and men while controlling for 
differences in age, sex, tumor site, surgical treatment, and 
Charlson comorbidity scores.
MATERIALS AND METHODS
Study Design, Setting, and Population
We conducted a retrospective cohort analysis with data 
from Kaiser Permanente Northern California (KPNC), a 
large integrated health care system. KPNC provides med-
ical care to more than 4 million members in Northern 
California and maintains clinical, demographic, and so-
cioeconomic data for more than 10 million past health 
care plan members.28,29 The Institutional Review Board 
at KPNC approved the study, providing a waiver of 
informed consent.
Outcome Measurement
Patients with HNC, aged 18 to 85 years and diagnosed 
with squamous cell carcinoma between 2000 and 2015, 
were included. Patients at stage I or IVC according to 
the seventh edition of the American Joint Committee 
on Cancer system or at Surveillance, Epidemiology, 
and End Results (SEER) summary stage 1, 7, or 9 were 
excluded, as were those who were diagnosed or treated 
outside of KPNC. The date of death was determined 
from hospital records, California state death certifi-
cates, and Social Security Administration data. The 
cause of death was determined from patients’ linked 
state death certificates. If a known death could not be 
linked to a primary cause of death, the patient chart was 
manually reviewed by the study’s clinical investigators. 
Cause-specific death was defined as death from can-
cer, whereas death from any other cause was considered 
a competing event. Treatment information, including 
chemotherapy, radiation, and surgery, was collected 
from the medical record. Intensive therapy was defined 
as concurrent therapy with cisplatin and radiation. 
Each patient’s age, race/ethnicity (non-Hispanic white, 
Asian, black, non-Asian/nonblack Hispanic, or other), 
sex, cancer site, cancer stage, self-reported smoking his-
tory, and alcohol abuse diagnostic history were also col-
lected from the medical record. As for the census-based 
socioeconomic status, each patient’s address at the time 
of diagnosis was used to determine his or her neighbor-
hood median income. A patient’s diagnosis and utili-
zation history in the year before the HNC diagnosis 
were used to calculate the Charlson Comorbidity Index 
(CCI; modified to exclude cancer in the calculation).30
Statistical Analysis
Our primary interest was to compare cancer mortal-
ity and treatment outcomes between women and men. 
Baseline characteristics, stratified by patient sex, were 
calculated and compared with chi-square tests. The 
cumulative incidence of cancer-specific and noncancer 
deaths through the first 5 years of follow-up, stratified 
on patient sex, was plotted with the cumulative incidence 
function. Patients were censored at the end of the study 
(December 2016) or if they disenrolled from KPNC. 
Disenrollment was defined as the end of membership or 
a gap in membership exceeding 3 months.
We used a multivariable GCE model (the gcer-
isk package in R) to estimate effects of covariates on 
the (adjusted) ratio of the hazard for cancer death to 
the hazard for competing mortality (the ω+ ratio). An 
ω+ ratio greater than 1 indicates that a covariate cate-
gory has a higher mean ω+ with respect to the baseline 
category. We used a GCE model based on Cox pro-
portional hazards regression, verified by inspection 
for proportional hazards, and controlling for age, sex, 
tumor site, surgical treatment, and CCI (binary: 0 vs 1 
or more comorbidities).24,31
We then used logistic regression to estimate the 
odds of receiving intensive treatment (ie, cisplatin with 
radiation), any radiation, or surgery, adjusting for the 
same covariates used in the GCE model plus cancer 
stage, smoking, and alcohol abuse history. For sensi-
tivity analyses, all GCE and logistic regression models, 
stratified by oropharyngeal HNC versus other HNC 
sites, were repeated. Because the magnitude and direc-
tion of the main effects were consistent and the power 
was low on account of the small sample sizes, the 
results from the sensitivity analyses are not presented 
here.
RESULTS
Between 2000 and 2015, we identified 884 patients di-
agnosed with HNC who met the inclusion and exclusion 
criteria (Fig. 1 and Table 1). The median follow-up was 
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2.9 years with a maximum follow-up of 16.8 years. Two 
hundred seventy one patients died of cancer (82 women 
and 189 men), and 93 patients died of noncancer causes 
(19 women and 74 men). One hundred six patients (12%) 
were censored because of disenrollment. In comparison 
with men, the cumulative incidence of cancer-specific 
death was higher for women (P = .03), whereas the cu-
mulative incidence of noncancer death was slightly lower 
(P = .10; Fig. 2A,B).
In our cohort, the male-to-female ratio was 3:1 (661 
men and 223 women; Table 1). The median age was 
higher for women at 64 years than for men at 60 years 
(P < .001). There was also a difference in the distribution 
of cancer sites between women and men (P < .001), with 
a higher incidence of oropharyngeal cancer in men than 
women (55% vs 38%). Men also had a lower incidence 
of oral cavity cancer (13% vs 28%). The distributions 
for race, neighborhood median income, smoking status, 
alcohol abuse history, and CCI were similar between 
women and men (Table 1).
The mean ω+ for women was 7.0, whereas the mean 
ω+ for men was 3.8; this indicated that compared with 
men, women had a higher hazard for cancer mortality 
with respect to death from competing events. Because 
the ω+ scores for women and men were both greater than 
1, both populations were more likely to die of their HNC 
than other causes. However, the ratio or difference be-
tween the cancer and noncancer death proportions was 
smaller for men than women. A higher ω+ could be expl-
ained by presentation with a more advanced or aggressive 
malignancy, a better baseline health status, a lower pro-
pensity to die of competing causes, undertreatment, or 
a combination of these factors. After we had controlled 
for other baseline covariates, the adjusted ω+ ratio com-
paring women with men was 1.95 (95% CI, 1.09-3.49). 
The ω+ ratio was lower for patients with increasing age 
per 10 years (0.77; 95% CI, 0.61-0.98) and for those who 
had surgery (0.52; 95% CI, 0.30-0.89). Patients with oral 
cavity primaries had a higher adjusted ω+ ratio (1.82; 
95% CI, 0.92-3.58), but this effect only reached border-
line significance (Fig. 3).
Compared with men, women were less likely to 
receive cisplatin concurrently with radiation (34% vs 
44%; P = .008) and radiation (60% vs 70%; P = .008; 
Table 1). With adjustments for covariates, women had 
lower odds of receiving cisplatin concurrently with radia-
tion (adjusted odds ratio [OR], 0.69; 95% CI, 0.48-0.99) 
and borderline lower odds of receiving any radiation 
(adjusted OR, 0.79; 95% CI, 0.56-1.12). Similarly, those 
with a CCI ≥ 1 (OR, 0.72; 95% CI, 0.51-1.00), oral cav-
ity cancer (OR, 0.43; 95% CI, 0.23-0.80), and increasing 
age (per 10 years; OR, 0.83; 95% CI, 0.71-0.96) were less 
likely to receive cisplatin with radiation. We also found 
that with increasing age, fewer patients received radia-
tion (adjusted OR, 0.90; 95% CI, 0.77-1.04) or surgery 
as part of their treatment (OR, 0.69; 95% CI, 0.58-0.82). 
Patients with oral cavity cancer were less likely to receive 
radiation than the cohort as a whole (OR, 0.32; 95% CI, 
0.19-0.52) but more likely to receive surgery (9.90; 95% 
CI, 5.61-17.97; Table 2).
DISCUSSION
Our principal findings from a large, diverse cohort of 
patients from KPNC with HNC were the following: 1) 
Figure 1. Cohort of patients with squamous cell carcinoma of the head and neck. KPNC indicates Kaiser Permanente Northern 
California; unk, unknown.
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the cumulative incidence of cancer-specific death was 
higher for women than men, but women had a lower 
rate of competing mortality in comparison with men 
(Fig 2A,B); 2) the ratio or difference of cancer death to 
noncancer death was greater for women; and 3) women 
were less likely to receive intensive treatment than men. 
Taken together, these findings indicate that women 
with HNC in our cohort appear to be undertreated. 
Our findings also provide support for the use of GCE 
analysis to identify disparities in the care of patients 
with cancer.
Our findings on GCE analysis accounted for es-
tablished risk factors, including age, site of the primary 
tumor, surgical treatment, and comorbidities. The ω+ 
ratio (ie, ω+ for women over ω+ for men) was approx-
imately 2 times higher for women in comparison with 
men, and this finding indicates an increased hazard of 
cancer death along with a concurrent decreased hazard 
of noncancer death, regardless of the primary cancer 
location.
Our finding that fewer women received intensive 
therapy in comparison with men remained significant 
even though we controlled for age, site of the primary 
tumor, surgical treatment, comorbidities, stage, smoking 
history, and alcohol history. Thus, when we controlled 
for each of these factors, women had higher cancer- 
specific mortality and lower competing mortality in 
comparison with men, and this signified undertreatment. 
Similar sex disparities in treatment have been reported 
for other types of cancer, including bladder cancer,32 
pancreatic cancer,33 kidney cancer,34 colon cancer,35 and 
lymphoma.36 Regarding the undertreatment of women 
with HNC, we hypothesize that other unmeasured fac-
tors, including an implicit physician bias and variation 
in patient treatment goals, may contribute to the lower 
utilization of intensive therapy that we observed.
Unlike prior studies that evaluated sex disparities 
in HNC mortality,11,19-23 our study examined the ratio 
of cancer mortality to noncancer mortality. In addi-
tion, our data source, the KNPC database, is advanta-
geous because it has a large, diverse patient population 
with demographic characteristics similar to those of the 
larger California community with respect to age, sex, 
and ethnicity.29 In contrast, data from clinical trials have 
less treatment variation, and comorbidity data are typi-
cally lacking; SEER-Medicare data are age-skewed and 
not representative of the overall population; the SEER 
database lacks sufficient treatment detail, progression, 
and comorbidity data; the National Cancer Database 
lacks cause-specific outcomes; the Veterans Affairs da-
tabase has few women; and single-institution databases 
often have limited sample sizes, which constrain power 
for competing event analyses. This lends insight into why 
other analyses that examine only composite endpoints, 
such as progression-free survival or overall survival, can 
easily overlook health disparities when they exist: as 
shown in Figure 2, although the overall probability of 
either cancer events or competing events could be similar 
between groups, their ratio could be quite different.
We acknowledge several limitations of our study. 
This was a retrospective, observational analysis. There 
were relatively few noncancer deaths in our population, 
and this potentially affected the stability of the GCE 
TABLE 1. Characteristics of Patients With Head 
and Neck Cancer From Kaiser Permanente 
Northern California
Characteristic
Women, No. 
(%)
Men, No.  
(%) Pa 
Total cases 223 (25.2) 661 (74.8)
Age at diagnosis .0002
21-40 y 12 (5.4) 21 (3.2)
41-50 y 18 (8.1) 94 (14.2)
51-60 y 61 (27.3) 218 (33.0)
61-70 y 64 (28.7) 214 (32.3)
71-80 y 53 (23.8) 95 (14.4)
81-85 y 15 (6.7) 19 (2.9)
Race/ethnicity .84
White 145 (65.0) 440 (66.6)
Black 16 (7.2) 40 (6.0)
Asian/Pacific Islander 38 (17.0) 98 (14.8)
Hispanic 15 (6.7) 54 (8.2)
Other/unknown 9 (4.1) 29 (4.4)
Census-based incomeb .57
Lower income 72 (32.3) 200 (30.3)
Higher income 151 (67.7) 461 (69.7)
Prior smoking 143 (64.1) 448 (67.8) .31
Prior alcohol abuse 40 (17.9) 123 (18.6) .82
CCI .98
0 140 (62.8) 412 (62.3)
1 43 (19.3) 132 (20.0)
≥2 40 (17.9) 117 (17.8)
Cancer stagec .003
IIA/IIB 52 (23.3) 94 (14.2)
III 56 (25.1) 159 (24.1)
IVA/IVB 115 (51.6) 408 (61.7)
Cancer site <.0001
Hypopharynx and larynx 32 (14.3) 106 (16.0)
Lip and oral cavity 62 (27.8) 88 (13.3)
Nasopharynx 45 (20.2) 95 (14.4)
Oropharynx 84 (37.7) 362 (54.8)
Salivary gland 0 (0) 10 (1.5)
Cisplatin chemotherapy + 
radiation
76 (34.1) 292 (44.2) .008
Any radiation 134 (60.1) 461 (69.7) .008
Radiation alone 39 (17.5) 114 (17.3) .93
Any surgery 96 (43.1) 270 (40.9) .56
Surgery alone 47 (21.1) 101 (15.3) .05
Abbreviation: CCI, Charlson Comorbidity Index.
aP values are based on the chi-square test.
bA lower income census tract was defined as a median neighborhood in-
come less than $60,000.
cAmerican Joint Committee on Cancer system, seventh edition.
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Figure 2. Cumulative incidence of (A) cancer death and noncancer death and (B) all-cause mortality.
A
B
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model. The human papillomavirus status and p16 testing 
for oropharyngeal cancers were not available. We did per-
form an additional analysis stratified by oropharyngeal 
cancer versus nonoropharyngeal cancer, and the mag-
nitude and direction of the covariate effects, including 
sex, were all similar, albeit with a power loss due to the 
sample size (data not shown). In addition, the determi-
nation of the cause of death was based on cancer registry 
data, which are far superior to death certificate data but 
remain imperfect.
In summary, we applied the GCE model to eval-
uate a large cohort of patients in Northern California 
with HNC with the goal of comparing cause-specific 
survival between women and men, and we found that 
women with HNC may be undertreated. Further inves-
tigation, particularly from large population-level data-
bases, may be able to confirm our findings and verify 
that our findings are consistent with the greater HNC 
population as a whole. If corroborated, our study will 
hopefully inform patients and physicians when they 
were considering treatment for HNC. Clinicians must 
remain vigilant when considering treatment options 
with their patients to avoid withholding potentially cu-
rative treatment because of fear of perceived harms in 
the face of evidence demonstrating that women may be 
undertreated.
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